Skip to Main Content

The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned again this week when Lupin, one of India’s biggest drug companies, hired an agency official who oversaw manufacturing facilities, including a plant that has been cited for ongoing problems.

The company hired Diana Amador-Toro as senior vice president for global compliance after she spent more than 38 years working at the FDA, where she was most recently district director at the New Jersey office and also a division I director in the Office of Pharmaceutical Quality Operations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment